RIPK2

Across TCGA pan-cancer cohorts, RIPK2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of RIPK2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RIPK2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RIPK2 is over-expressed in tumor.

HNSC, BLCA, and COAD are the cancer types where RIPK2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RIPK2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	III,IV	+1.321	<.001	12	view →
BLCA	All	IV	+1.085	<.001	12	view →
COAD	Female	III,IV	+2.064	<.001	11	view →
KIRC	Male	IV	+1.230	<.001	11	view →
STAD	All	III,IV	+1.775	<.001	10	view →
LIHC	Male	II,III,IV	+1.309	<.001	8	view →
READ	Male	All	+2.243	<.001	7	view →
UCEC	All	II,III,IV	+1.200	<.001	6	view →
KIRP	All	II,III,IV	+1.035	<.001	6	view →
BRCA	All	All	+0.805	<.001	6	view →
ESCA	Male	All	+1.664	<.001	5	view →
THCA	All	III,IV	+0.406	.004	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

RIPK2–HNSC

Open the HNSC breakdown →